减肥新药不及预期，诺和诺德盘前暴跌近 30%！对手礼来大涨超 10%
Novo Nordisk stated on Friday that its next-generation obesity drug Cagrisema achieved only a 22.7% weight loss in a trial, below its expected 25%
A highly anticipated study shows that a dual-drug combination called CagriSema helped people lose an average of 22.7% of their weight after more than a year of weekly injections, while patients receiving a placebo lost 2.3%.
Novo Nordisk stated on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, falling short of its expected 25%, leading to a significant drop in its stock price.
Meanwhile, competitor Eli Lilly surged over 9% in pre-market trading after Novo Nordisk released the clinical data for CagriSema, which showed that patients lost 22.7% of their weight in the trial, below previous expectations
